Posted on August 12th, 2009 by Kelley Luckstein
An experimental drug has successfully reduced hip and spine fractures in the two largest patient populations at risk for osteoporosis — postmenopausal women and men being treated for prostate cancer — according to two major studies published online on Aug. 11 by the New England Journal of Medicine. The new compound, denosumab, is being reviewed by the Food and Drug Administration… "How much impact this would have on patient care remains to be seen," says Dr. Sundeep Khosla, a professor of medicine at the Mayo Clinic, who wrote an editorial accompanying the two studies in the Journal.
TIME by Alice Park,
You must be logged-in to the site to post a comment.